Skip to content
HowShorted

KalVista Pharmaceuticals, Inc. short interest in 2023

In 2023, KalVista Pharmaceuticals, Inc.'s disclosed short interest ran from 8.69% of shares outstanding on 13 Jan 2023 to 10.67% on 29 Dec 2023, a change of +1.98 percentage points. The year's high was 13.48% on 13 Oct 2023 and its low 7.20% on 15 Mar 2023, averaging 10.62% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 35.14 days on 31 Jul 2023. Full history: KalVista Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for KalVista Pharmaceuticals, Inc. in 2023

2023 in figures

Start of year
8.69% (13 Jan 2023)
End of year
10.67% (29 Dec 2023)
Change
+1.98 pp
High
13.48% (13 Oct 2023)
Low
7.20% (15 Mar 2023)
Average
10.62%
Highest days to cover
35.14 (31 Jul 2023)
SEC filings marked
8

Every report in 2023

KalVista Pharmaceuticals, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20238.69%6.74
31 Jan 202311.00%5.42
15 Feb 202310.98%9.55
28 Feb 20238.83%5.48
15 Mar 20237.20%8.8710-Q filed, results (8-K)
31 Mar 20237.92%8.84
14 Apr 20238.20%12.66
28 Apr 20239.60%14.53
15 May 202310.02%15.67
31 May 202310.51%16.00
15 Jun 202310.93%20.37
30 Jun 202310.97%20.55
14 Jul 202311.40%23.5410-K filed, results (8-K)
31 Jul 202311.65%35.14
15 Aug 202311.96%15.31
31 Aug 202311.28%15.59
15 Sep 202311.81%15.6010-Q filed, results (8-K)
29 Sep 202312.88%19.56
13 Oct 202313.48%9.57
31 Oct 202312.03%20.40
15 Nov 202311.64%12.69
30 Nov 202311.17%16.29
15 Dec 202310.09%8.4210-Q filed, results (8-K)
29 Dec 202310.67%9.51

See also: KalVista Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.